Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD

Bibliographic Details
Main Authors:	Pavord, I, Kerstjens, H, Korn, S, Criner, G, Sagara, H, Rubin, D, Harris, S, Mayer, B, Bradford, E, Albers, F, Yancey, S
Format:	Conference item
Published:	European Respiratory Society 2017

Similar Items

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
by: Pavord, I, et al.
Published: (2017)

Mepolizumab for eosinophilic COPD
by: Sciurba, F, et al.
Published: (2018)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
by: Bafadhel, M, et al.
Published: (2018)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
by: Gunsoy, N, et al.
Published: (2017)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
by: Chapman, K, et al.
Published: (2018)

Glucocorticoids and mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2018)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

Mepolizumab treatment in patients with severe eosinophilic asthma.
by: Ortega, H, et al.
Published: (2014)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
by: Ortega, H, et al.
Published: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
by: Yancey, S, et al.
Published: (2016)

Mepolizumab in refractory eosinophilic asthma.
by: Pavord, I, et al.
Published: (2010)

Mepolizumab, quality of life, and severe eosinophilic asthma.
by: Pavord, I
Published: (2017)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
by: Ian D. Pavord, et al.
Published: (2022-05-01)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
by: Moran, AM, et al.
Published: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
by: Haldar, P, et al.
Published: (2009)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
by: Wechsler, M, et al.
Published: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
by: Pavord, I, et al.
Published: (2012)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2017)

Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
by: Bafadhel, M, et al.
Published: (2018)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
by: Shrimanker, R, et al.
Published: (2017)

Biomarkers for severe eosinophilic asthma.
by: Yancey, S, et al.
Published: (2017)

The significance of eosinophilic inflammation in COPD
by: Cooper, C, et al.
Published: (2017)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
by: Benjamin Terrier, et al.
Published: (2023-07-01)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
by: Moran, A, et al.
Published: (2020)

Seasonality of eosinophilic and non-eosinophilic exacerbations of COPD
by: Barker, R, et al.
Published: (2017)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
by: Ian Pavord, et al.
Published: (2023-04-01)

Eosinophils in COPD: just another biomarker?
by: Bafadhel, M, et al.
Published: (2017)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
by: V. N. Drozdov, et al.
Published: (2020-11-01)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
by: Giuseppe A. Ramirez, et al.
Published: (2022-12-01)

Exacerbations of severe asthma in patients treated with mepolizumab
by: Shrimanker, R, et al.
Published: (2018)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
by: Haldar, P, et al.
Published: (2014)

Mepolizumab as an effective treatment in a case of hypophysitis in eosinophilic granulomatosis with polyangiitis
by: Jessy Chen, et al.
Published: (2023-06-01)

Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis
by: Moriyasu Anai, et al.
Published: (2022-04-01)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
by: Andrea Portacci, et al.
Published: (2023-10-01)

Mepolizumab For The Treatment Of Patients With Eosinophilic Granulomatosis With Polyangiitis: A Phase Iii Randomized, Placebo-Controlled Trial
by: Wechsler, M, et al.
Published: (2017)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Blood eosinophil levels as a biomarker in COPD
by: Brusselle, G, et al.
Published: (2018)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
by: I. J. Pouliquen, et al.
Published: (2017-11-01)